Thus, the application of preosteoclasts to biomineralized matrix for osteoclastogenesis is a physiologically relevant strategy for osteoclast introduction.
In this article we present a relevant strategy for a non-trivial time-programmed release of water-soluble macromolecules from biocompatible μ-containers.
It is interesting to note that several studies also suggest the relevance of combined inhibition of CRAF and BRAF in a BRAF mutant context for efficacy and may prove to be relevant strategy for treatment of both NRAS and BRAF mutant melanomas [34], [35].
Hence, the impairment of oligomerization of helices by using designed small molecule inhibitors such as short peptides is a therapeutically relevant strategy for the prevention of T2DM.
Thus, the therapeutic benefit of IGF-1 in these models offers a clinically relevant strategy for the treatment of skin inflammation in ACD.
Inhibition of the VEGF/VEGFR system has already become a clinically relevant strategy for innovative treatment of several urological tumours (Krause and Van Etten, 2005; Chieffi, 2007).
The Treg cell-dependent clinical benefit of IGF-1 in this model offers both mechanistic insights into ACD and a clinically relevant strategy for therapeutic application.
We can consider that defining disease severity from the patient's perspective may be a relevant strategy for the daily clinical management of patients with OA.
